Compare WEYS & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEYS | ENTA |
|---|---|---|
| Founded | 1906 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 331.9M | 382.7M |
| IPO Year | 1995 | 2012 |
| Metric | WEYS | ENTA |
|---|---|---|
| Price | $36.00 | $11.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.40 |
| AVG Volume (30 Days) | 13.2K | ★ 187.1K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.24% | N/A |
| EPS Growth | N/A | ★ 29.93 |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $276,169,000.00 | $102,814,000.00 |
| Revenue This Year | N/A | $7.76 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $56.53 | ★ N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $27.25 | $6.44 |
| 52 Week High | $36.58 | $17.15 |
| Indicator | WEYS | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 61.80 | 40.53 |
| Support Level | $30.62 | $10.21 |
| Resistance Level | N/A | $13.97 |
| Average True Range (ATR) | 1.35 | 0.75 |
| MACD | 0.09 | -0.08 |
| Stochastic Oscillator | 100.00 | 30.15 |
Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale operations and the North American retail operations. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, South Africa, and Australia.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.